Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: Mar 20, 2026

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Published on: August 18, 2023

Cell-Based Therapies Formulations: Unintended components.

¹United States Pharmacopeial Convention, Rockville, Maryland, USA. fa@usp.org.

The AAPS Journal

|May 29, 2016

Summary

Cell-based therapies offer regenerative medicine opportunities but face challenges in ensuring raw material quality. This review discusses qualifying excipients and ancillary materials for safe and effective cell therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Review of Quality Attributes and Analytical Methods Used for Comparative Analytical Assessment of Monoclonal Antibodies as Part of Successful Biosimilar Approvals in the United States and European Union.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026

Same author

Reference Standards to Support Quality of Synthetic Peptide Therapeutics.

Pharmaceutical research·2023

Same author

Correction to: Cell-Based Therapies Formulations: Unintended Components.

The AAPS journal·2022

Same author

USP Reference Standard Monoclonal Antibodies: Tools to Verify Glycan Structure.

Pharmaceuticals (Basel, Switzerland)·2022

Same author

A Reference Standard for Analytical Testing of Erythropoietin.

Pharmaceutical research·2022

Same author

Biopharmaceutical Industry Capability Building in India: Report from a Symposium.

Journal of pharmaceutical innovation·2021

Area of Science:

Regenerative Medicine
Cell-based Therapy
Biologics Manufacturing

Background:

Cell-based therapy is a rapidly advancing area of regenerative medicine.
Living cells are used as active pharmaceutical ingredients for tissue regeneration.
Challenges exist in controlling the quality of cell therapy products.

Purpose of the Study:

To discuss challenges and opportunities in qualifying raw materials for cell therapy manufacturing.
To highlight the importance of excipient and ancillary material quality.
To review quality control strategies in cell-based product development.

Main Methods:

Review of current literature on cell therapy manufacturing.
Analysis of quality control challenges for raw materials.

Keywords:

ancillary material cell-based therapy excipient formulation

More Related Videos

Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity

Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity

Published on: November 8, 2016

Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye

Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye

Published on: March 30, 2020

Related Experiment Videos

Last Updated: Mar 20, 2026

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production

Published on: August 18, 2023

Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity

Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity

Published on: November 8, 2016

Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye

Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye

Published on: March 30, 2020

Discussion of regulatory considerations for excipients and ancillary materials.

Main Results:

Excipients and ancillary materials are critical for cell therapy safety and quality.
Qualification of these raw materials presents significant challenges.
Opportunities exist to improve manufacturing processes through rigorous material control.

Conclusions:

Ensuring the quality of raw materials is paramount for successful cell-based therapies.
Standardized qualification processes for excipients and ancillary materials are needed.
Further research into material characterization can enhance therapeutic product safety and efficacy.